Kyverna Therapeutics, Inc. (KYTX)
Nasdaq: KYTX · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2023
Who owns Kyverna Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Dr. Beth C. Seidenberg ("Seidenberg") holds 7.8% of Common Stock, par value $0.00001 per share, as its SCHEDULE 13G/A filed Feb 6, 2026 says.
Directors and officers
14
report now, of 21 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Dr. Beth C. Seidenberg ("Seidenberg")
SCHEDULE 13G/A · filed Feb 6, 2026 · Common Stock, par value $0.00001 per share
GordonMD Global Investments LP
SCHEDULE 13G · filed Nov 17, 2025 · Common Stock, par value $0.00001 per share
Michael P. Rubin
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share
Orin Hirschman
SCHEDULE 13G · filed Oct 19, 2026 · Common Stock, par value $0.00001 per share
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock
Bain Capital Life Sciences Opportunities III, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 5.4% in Feb 17, 2026
What KYTX reports owning in othersstakes of 5% or more, and other ties
Kyverna Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
1sales
1purchases
1sales on a scheduled plan
1people selling
$300,000sold, in dollars
$1.0Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Walker Karen Marie | Chief Technology Officer | 1 | $300,000 | 1 | 0 | $0 |
| Seidenberg Beth C | director | 0 | $0 | 0 | 1 | $1.0M |
| Westlake Biopartners Opportunity Fund I, L.P. | 10% owner | 0 | $0 | 0 | 1 | $1.0M |